http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 04 Jan 2026 17:30:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54383051&amp;newsitemid=20260105027779&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=d0c9e1f2202f673820259bc95c259fb9" shape="rect">Orum Therapeutics</a> (Orum or the Company) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Chad May, Ph.D., as Chief Scientific Officer (CSO). Dr. May brings more than 20 years of oncology and immunology research experience with a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. </p><p> “Chad has repeatedly demonstrated an ability to take bold scientific concepts and advance them into clinical candidates across multiple therapeutic modalities,” said http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Appoints+Chad+May+as+Chief+Scientific+Officer+to+Drive+Degrader-Antibody+Conjugate+Innovation+and+Programs/25799891.html Sun, 04 Jan 2026 17:30:00 -0500 475830 A.26328461 A.41307835 O.01239210 O.21915320 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Press+Releases/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892 http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html <ul class="bwlistdisc"> <li> <i>Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations</i> </li> <li> <i>Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage of growth and reinforcing Orum’s position as a leader in next-generation DACs</i> </li> </ul> <p> BOSTON &amp; DAEJEON, South Korea--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.orumrx.com%2F&amp;esheet=54378348&amp;newsitemid=20251216175984&amp;lan=en-US&amp;anchor=Orum+Therapeutics&amp;index=1&amp;md5=60300dc7e163e3bd45f64c6793bd5f21" shape="rect">Orum Therapeutics</a> (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced http://www.streetinsider.com/Business+Wire/Orum+Therapeutics+Secures+Approximately+US%24100+Million+to+Accelerate+Development+of+Leading+Degrader+Antibody+Conjugate+Programs+to+Treat+Serious+Diseases/25754896.html Thu, 18 Dec 2025 03:25:00 -0500 105560 475830 A.07901388 A.50201906 A.50208121 KB O.04958459 O.04958865 O.06038902 O.25719531 O.37865892